上海优宁维生物科技股份有限公司(以下简称"公司")于 2025 年 4 月 10 日召 开第四届董事会第四次会议、第四届监事会第四次会议，于 2025 年 5 月 13 日召 开 2024 年度股东大会，审议通过了《关于回购公司股份方案的议案》，同意公 司使用不低于人民币 1,500 万元（含本数），不高于人民币 3,000 万元（含本数） 的自有资金以集中竞价交易方式回购公司部分无限售条件的 A 股流通股，用于 注销并减少注册资本，回购价格不超过人民币 44 元/股（含本数，下同），回购 期限自公司 2024 年度股东大会审议通过本次回购股份方案之日起 12 个月内。具 体内容详见公司于 2025 年 4 月 14 日及 2025 年 5 月 13 日刊登在巨潮资讯网的《关 于回购公司股份方案的公告》《回购报告书》。 公司 2024 年度权益分派于 2025 年 5 月 22 日实施完毕，根据《关于回购公 司股份方案的公告》《回购报告书》，公司本次以集中竞价交易方式回购股份价 格上限由不超过人民币 44 元/股调整为不超过人民币 43.77 元/股，回购价格调整 起始日为 2025 年 5 月 22 日（除 ...

经济观察网2026年1月30日，优宁维（301166）发布2025年度业绩预告，预计2025年净利润亏损1500万 元至3000万元。扣除非经常性损益后的净利润亏损3448万元至4948万元。 ...

南财智讯1月30日电，优宁维发布2025年度业绩预告，预计2025年全年归属于上市公司股东的净利润为 亏损1500万元—3000万元；预计2025年全年归属于上市公司股东的扣除非经常性损益的净利润为亏损 3448万元—4948万元。业绩变动原因说明：1、预告期内，公司业绩亏损的主要原因为：2025年，围 绕"两个极致"战略，公司持续加强第三方品牌和自主品牌业务的协同，依托现有销售资源和持续研发投 入，公司自主品牌业务实现较高增长，带动公司整体毛利率较上年同期有所提升，公司产品和收入结构 进一步优化；公司通过业务赋能和创新，2025年各季度收入同比降幅持续收窄，有效带动全年收入降幅 较2024年度进一步收窄。与此同时，受市场需求尚未明显复苏，公司整体收入仍未达预期；公司整体毛 利率虽在自主品牌业务带动下有所增长，但仍处于公司过往较低水平；报告期内，公司为继续保持渠道 优势和提升产品能力，公司在销售费用与研发费用方面，持续维持较高比例投入。公司将积极推动产品 结构转型，力争实现盈利能力和销售业绩的双增长。2、报告期内，公司非经常性损益预计为1948万 元，主要系银行现金管理收益及政府补贴。 ...

（一）业绩预告期间 2025 年 1 月 1 日至 2025 年 12 月 31 日。 （二）业绩预告情况：预计净利润为负值 | 项 目 | | 本报告期 | | 上年同期 | | | --- | --- | --- | --- | --- | --- | | 归属于上市 公司股东的 | | | 万元 | | 万元 | | | 亏损：1,500 | 万元-3,000 | | 盈利：1,014.9 | | | 净利润 | | | | | | | 扣除非经常 | | | | | | | 性损益后的 | 亏损：3,448 | 万元-4,948 | 万元 | 亏损：1,511 | 万元 | | 净利润 | | | | | | 证券代码：301166 证券简称：优宁维 公告编号：2026-005 上海优宁维生物科技股份有限公司 2025 年度业绩预告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有 虚假记载、误导性陈述或重大遗漏。 一、本期业绩预计情况 毛利率虽在自主品牌业务带动下有所增长，但仍处于公司过往较低水平；报告期 内，公司为继续保持渠道优势和提升产品能力，公司在销售费用与研发费用方面， 持续维 ...

Core Viewpoint - The company, Youningwei, announced the completion of two laboratory projects and the subsequent cancellation of related fundraising accounts, transferring a total of 66.11 RMB to its general account for operational liquidity [2]. Group 1: Project Completion - Youningwei has completed the "Aibixin (Shanghai) Biotechnology Co., Ltd. Laboratory Construction Project" and the "Shanghai Lebishi Biotechnology Co., Ltd. Laboratory Adjustment Project" [2]. Group 2: Fund Management - In accordance with relevant regulations, the company has canceled the fundraising accounts associated with the completed projects to streamline bank account management and reduce management costs [2]. - The remaining funds, including interest, amounting to 66.11 RMB, have been transferred to the company's general account for daily operational liquidity [2]. - The cancellation of the fundraising accounts also leads to the termination of the corresponding regulatory agreements [2].

证券代码：301166 证券简称：优宁维 公告编号：2026-004 上海优宁维生物科技股份有限公司 二、募集资金的存放和管理情况 为规范公司募集资金管理和使用，保护投资者权益，根据《上市公司监管指 引第 2 号——上市公司募集资金管理和使用的监管要求》《深圳证券交易所创业 板股票上市规则》《深圳证券交易所上市公司自律监管指引第 2 号——创业板上 市公司规范运作》等相关法律、法规和规范性文件及公司《募集资金管理办法》 的规定，公司开立了募集资金专项账户，对募集资金实行专户存储，并与保荐机 构民生证券股份有限公司及商业银行签订了《募集资金三方监管协议》。具体内 容详见《关于签署募集资金三方监管协议的公告》（公告编号 2022-003、2022-047、 2024-075）。 截至本公告披露日，公司及全资子公司募集资金专户的开立及存续情况如 下： | | | | 线上营销网络与信息化建设项目； | 98250078801000002003 | 上海浦东发展银行股份有限公司 | 存续 | | --- | --- | --- | --- | | 线下营销及服务网络升级项目 | | 南市支行 | | | 补充流动资金 ...

Core Viewpoint - The company emphasizes its commitment to stabilizing stock price fluctuations through improved operational performance, share buybacks, and enhanced communication with investors [1] Group 1: Stock Price Management - The company is focused on maintaining stable stock price fluctuations by enhancing operational performance [1] - The company plans to utilize share buybacks as a strategy to support stock price stability [1] - The company is committed to strengthening communication with investors to foster trust and transparency [1] Group 2: Future Plans and Regulations - The company will consider implementing equity incentive measures in line with its development needs and regulatory requirements [1] - Profit distribution will be conducted in strict accordance with relevant laws and regulations, taking into account the overall interests of all shareholders and sustainable development [1] - The company will fulfill its information disclosure obligations promptly as developments occur, encouraging investors to pay attention to future announcements [1]

Core Viewpoint - The company emphasizes the importance of information technology in enhancing its business operations as a one-stop supplier in the life sciences sector [1] Group 1: Business Strategy - The company is continuously upgrading its online marketplace and has launched systems such as UCRM, CRM, laboratory management systems, OA, and OMS to improve business and management efficiency [1] - The company leverages big data technology to refine customer profiles based on accumulated customer data, enabling more precise product and service offerings [1] Group 2: Future Developments - The company plans to stay updated on advancements in information technology and actively embrace developments in artificial intelligence to empower its proprietary product development [1] - The company aims to launch market-targeted products based on the latest technological advancements [1]

Group 1 - The core business of the company includes providing life science reagents, instruments, consumables, and comprehensive technical services, with revenue composition being 77.94% from life science reagents, 16.11% from instruments and consumables, and 5.95% from technical services [1] - As of January 22, the company's financing balance is 57.40 million yuan, accounting for 2.03% of the market capitalization, indicating a high level compared to the past year [1] - The company reported a decrease in revenue of 6.24% year-on-year for the period from January to September 2025, with total revenue of 776 million yuan and a net profit attributable to shareholders of -15.08 million yuan, a significant decline of 207.11% [2] Group 2 - The number of shareholders decreased by 13.19% to 9,893 as of September 30, while the average circulating shares per person increased by 15.19% to 5,753 [2] - The company has distributed a total of 182 million yuan in dividends since its A-share listing, with 138 million yuan distributed in the last three years [3] - As of September 30, 2025, the top ten circulating shareholders include a new shareholder, Nuoan Multi-Strategy Mixed A, holding 499,100 shares [3]

Core Viewpoint - The company is focused on a one-stop platform strategy and antibody strategy, aiming to find relevant target enterprises in the upstream and downstream application fields of antibodies for synergistic development with existing businesses [2] Group 1 - The company is committed to exploring investment opportunities through equity investment funds to identify suitable targets for external development [2] - The company emphasizes the importance of timely information disclosure regarding any significant progress in its investment activities [2] - Investors are encouraged to pay attention to the company's future announcements related to these developments [2]